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There is accumulating evidence but no definitive answers about the incidence of depressed mood in the menopause
transition and its association with the changing hormonal milieu. While a changing hormonal milieu is the natural
condition for all women, only a minority of mid-life women experience debilitating depressive symptoms or clinical
depression. This review focuses on associations between depressed mood and the menopause transition, primarily
as identified in longitudinal, population-based studies in the past decade. Further aims were to present reported
associations between depressed mood and reproductive hormones in the menopause transition as evaluated in
the general population and associations of depressive symptoms or clinical depression with menopausal hot
flashes or poor sleep in perimenopausal women. There is evidence to support the role of the changing endocrine
milieu in the development of depressed mood in the menopause transition, but the contribution of hormones as
measured is small. Disentangling the numerous factors that are associated with depression in midlife women is a
major challenge for research and for clinical care, where treatments are needed to improve the most distressing
menopausal symptoms.
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Changes in menstrual bleeding patterns signal the ap-
proach of menopause in mid-life women, and many
women report hot flashes, poor sleep, depressed mood
and other symptoms along with these menstrual
changes. The extent to which symptoms that arise
around menopause are directly associated with the hor-
mone changes of ovarian aging is not well understood.
There is accumulating evidence but no definitive an-
swers about many potential risk factors and the role of
the changing hormone milieu associated with depressed
mood around menopause. Further information is clinic-
ally important, because of the diminished functioning
and significant disability that accompany depression
[1, 2], the exacerbation of disorders associated with
the neuroendocrine system [3], and the associationsCorrespondence: freemane@mail.med.upenn.edu
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cardiovascular disease [4–6], metabolic syndrome [7–9]
and osteoporosis [10, 11], that complicate treatments and
contribute substantially to disability and the high costs of
health care.
Depressive symptoms are common in all populations
but appear to increase among women in the transition
to menopause. Major depression is more common in
women than in men in all age groups until late life, with
a lifetime prevalence of 21 % compared to 12 % for men
in the National Comorbidity Survey [12]. Depression in
women also appears to increase around reproductive
events. Postpartum depression following childbirth, pre-
menstrual dysphoric disorder linked to the menstrual
cycle, and depression around menopause may possibly
share a sensitivity to normal shifts in reproductive hor-
mones, which in turn modulate neuroregulatory systems
associated with mood and behavior [13, 14]. However,
definitive answers about these associations, the etiologyle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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changes in depressive disorders have been elusive.
Reports pertaining to depression around menopause
have changed over the years. In 2005, the National
Institutes of Health (NIH) issued a State-of-Science re-
view of the management of menopause-related symp-
toms, which concluded that evidence for associations
between depressed mood and menopausal status was
poor or mixed [15]. Another review of prospective co-
hort studies that assessed mood symptoms of mid-life
women around menopause similarly concluded that
there was no clear evidence of an independent effect of
the menopause transition on depression [16]. These con-
clusions stimulated further research leading to more pre-
cise definitions of menopausal status and the use of
standard measures of depressive symptoms or depressive
disorders. Subsequently, multiple, but not all, population-
based studies reported an increased prevalence of depres-
sive symptoms in the menopause transition compared to
premenopausal women [17]. Some studies differentiated a
first-onset depression from a history of depression in
perimenopausal women. The studies overall showed
that both women with a history of depression and
women with no history of depression had an increased
risk of depressive symptoms and possibly an increased
risk of depressive illness around menopause, but the
prevalence was significantly greater among women with
a history of depression [18–20].
The aims of this review were to examine associations
between depressed mood and the menopause transition,
focusing on longitudinal studies in the general popula-
tion. Further aims were to present reported associations
of reproductive hormones with depression in the meno-
pause transition, observed associations between depres-
sive symptoms and menopausal hot flashes or poor
sleep, which have been identified as risk factors for de-
pressive symptoms or clinical depression in perimeno-
pausal women. The review did not include intervention
studies, neuroendocrine studies, animal models, or stud-
ies of postmenopausal women. These domains are
clearly important for understanding the development of
depression around menopause but are beyond the range
of this review and are examined elsewhere [14, 21–29].
Review
Common menopausal symptoms
More than 80 % of women experience physical or psy-
chological symptoms around menopause, with varying
degrees of severity and disruption in their lives [30, 31].
Depression and other mood changes, hot flashes and
sleep difficulties are among the most frequently reported
menopausal symptoms [32, 33], although reports of
their prevalence and duration can vary widely, due in
part to differences in symptom measures, definitionsof menopausal status, retrospective or prospective ob-
servations in relation to menopause, cross-sectional study
designs, sample sizes, and adjustments for confounding
factors.
The menopause transition (perimenopause)
Menopause is defined post hoc after no menstrual bleed-
ing for at least 12 months [34]. In the classic longitu-
dinal study of Treloar, the mean age at menopause was
50.7 years, with a 95 % range of 44–56 years [34]. In the
Massachusetts Health Study of the normal menopause
transition, the median age at menopause was 51.3 years
[35]. The transition to menopause is marked by progres-
sively expanding variability in menstrual bleeding, which
results from the increasing frequency of anovulation as
the number of oocytes declines. The data of Treloar
show that this reproductive transition extends for 2 to
8 years before menopause, and that the age at onset of
the menopause transition ranges from 39 to 51 years for
95 % of women [34]. Thus, the mean duration of the
menopause transition is about 5 years, although both
the age at onset and the duration vary widely among
individuals, and factors such as smoking, obesity and
mood disorders may alter the timing or the duration of
the transition period [36–39].
The development of a staging system for reproductive
aging by the Stages of Reproductive Aging Workshops
(STRAW) led to considerable increases in information
about the rise of symptoms in relation to menstrual sta-
tus and potential associations between symptoms and
hormone changes of ovarian aging. The STRAW defini-
tions of stages of reproductive aging were based primar-
ily on observed bleeding patterns. The definitions were
further refined as data accumulated, with revised defini-
tions presented in STRAW+ 10 [40]. The STRAW-
defined stages in the menopause transition are early
transition (persistent difference of 7 days or more in the
length of consecutive menstrual cycle) and late transition
(amenorrhea of 60 days or longer). Postmenopause is di-
vided into early (2 years: +1a, +1b; and 3–6 years: +1c after
the final menstrual period) and late (the remaining
lifespan) stages. Perimenopause indicates the time
around menopause and extends from the early transi-
tion stage through 12 months after the final menstrual
period [40].
Prevalence of depression
The National Comorbidity Study reported 30- day es-
timates of major depression for women aged 45–54
years of 5.0 % and lifetime estimates of 21.8 % [41].
Depression tends to wax and wane with repeated epi-
sodes or persist in a chronic state, which occurs in
up to 35 % of depressed patients as reported by
Nierenberg [42]; a prior depression is the strongest
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of recurrent depression for women are highest in the
45–54 year age-group [41], which are the years proximal
to menopause. Consequently, recurrent depression may
coincide with the perimenopausal years, contributing to
reports of increased prevalence of depression around
menopause.
Depression and the menopause transition
An association between depression and menopausal
status is one of the most controversial issues in the
menopause transition. Epidemiologic studies based on
self-report of menopausal status and depressed mood
consistently indicated that most respondents did not
report high rates of depressive symptoms, and that
reported depressive symptoms were not associated
with menopause per se but with other health problems
[16, 43–46]. Bosworth et al. reported that 28.9 % of
women aged 45–54 years had a high level of depressive
symptoms based on an abbreviated CES-D scale but
found no association between the depressive symptoms
and menopausal status as defined by the women’s per-
ceptions [47]. In the Massachusetts Women’s Health
Study, there was an increased risk of depression in the
menopause transition but no significant association be-
tween the increased risk of depression (CES-D scores)
and the onset of menopause [43]. A subgroup of women
with a long transition period had an increased risk of de-
pression, but the causal direction could not be deter-
mined; the researchers speculated that the increased risk
could be explained by increased menopausal symptoms.
Early data from the large Study of Women’s Health
Across the Nation (SWAN) indicated that rates of
persistent mood symptoms were higher in early peri-
menopausal women than among premenopausal women
(18.4 versus 14.9 and 12 % versus 8 %, respectively) [48].
Dennerstein et al. defined perimenopause status from
bleeding patterns and reported that more late perimeno-
pausal women reported depressive symptoms in the pre-
vious 2 weeks (38 %) compared to premenopausal
(26 %) and postmenopausal women (28 %) [49]. In con-
trast to community-based samples, evaluation of women
attending a menopause clinic identified higher rates of
depressive disorders. Soares et al. reported that 28.7 % of
women ages 40–58 years in a menopause clinic met
DSM-IV criteria for depressive disorders [50]. These
studies all suggested an increased prevalence of depres-
sive symptoms and possibly depressive illness in the
transition to menopause.
As studies more specifically defined a menopause
transition period and systematically assessed depression
status, associations between depressive symptoms and
menopausal status were consistently observed in longi-
tudinal cohort studies.The Harvard Study of Moods and cycles found that
women with no history of depression were nearly twice
as likely to experience depression in the menopause
transition compared with premenopausal women (OR 1.8,
95 % CI:1.0 – 3.2) [36]. When adjusted for a history of
adverse life events and vasomotor symptoms, the risk of
depressive symptoms further increased to 2.5 times for
women in the menopause transition compared with pre-
menopausal women (OR 2.5; 95 % CI: 1.2 – 5.2).
In a series of studies in the Penn Ovarian Aging cohort
(POAS), the risk of depressive symptoms (CES-D scores)
was nearly three times greater in women in the meno-
pausal transition compared with premenopausal women,
after adjusting for other predictors of depression includ-
ing a history of depression, hot flashes, poor sleep, and
severe premenstrual syndrome (early transition OR 1.55,
95 % CI: 1.04 – 2.32 and late transition OR 2.89,
95 % CI: 1.29 – 6.45) [51]. In a further study of
women with no history of depression, the risk of
CES-D depression was more than four times greater in
the menopause transition compared with when the same
women were premenopausal (OR 5.44; 95 % CI: 2.56 –
11.59 in adjusted analysis) [19]. When only women who
had a DSM-IV clinical diagnosis of depression were eval-
uated, the odds of the onset of a diagnosed depressive
disorder were significantly greater in the menopause
transition compared with the woman’s own premeno-
pausal period (OR 1.60; 95 % CI: 1.25 – 5.02 in adjusted
analysis) [19]. When depressive symptoms (high CES-D)
were evaluated across 14 years of follow-up relative
to the final menstrual period (FMP), the findings
demonstrated a pivotal role of the FMP in the risk of
depressive symptoms: there was a higher risk of high
depressive symptoms before and a lower risk after
the FMP [18].
A series of SWAN studies evaluated menopausal status
in relation to outcomes of dysphoric mood [48, 52],
depressive symptoms (CES-D) [53–55] and depressive
disorder [56, 57]. These studies overall showed that de-
pressive symptoms and dysphoric mood varied by meno-
pausal status and were independent of other known risk
factors for depression. Women were more likely to re-
port depressed mood (CES-D scores) in the menopause
transition and early postmenopausal years compared
with premenopause after adjusting for other demo-
graphic psychosocial, behavioral, and health factors [54].
The likelihood of depressive symptoms was significantly
higher in the early transition (OR 1.30; 95 % CI: 1.09 –
1.55), the late transition (OR 1.71; 95 % CI:1.27 – 2.30),
and postmenopause (OR1.57; 95 % CI: 1.15 – 2.15) com-
pared with premenopausal women [54]. Perimenopausal
women were nearly twice as likely to experience a major
depressive episode after adjusting for a history of depres-
sion, vasomotor symptoms, BMI, age, race, upsetting life
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3.92) [56]. The likelihood of experiencing an episode of
major depression during a 10 year follow-up did not dif-
fer between African American and Caucasian women
[56]. When African American women were hypothesized
to have greater persistence or recurrence of mood disor-
ders compared to Caucasian women, no significant dif-
ference in recurrence of depression was found between
African American and Caucasian women in 11 years of
follow-up [58].
The Seattle Midlife Women’s Health Study (SMWHS)
showed that depressive symptoms (CES-D scores) sig-
nificantly increased in the late menopause transition
stage after adjusting for multiple risk factors (beta 1.56,
SE 0.73, P = 0.032) [59]. Menopausal stage increased de-
pression scores more than age and the late transition
stage remained an independent factor after adjustment
for age, life stress, body mass index, history of postpar-
tum blues, and use of antidepressants, each of which
remained significantly associated with depressed mood
in the final adjusted model.
In the Melbourne study, depressive symptoms (a
shortened version of CES-D) were higher in women who
were in the early and late stages of the menopause tran-
sition compared to postmenopausal women [60]. CES-D
correlated with negative mood measured concurrently
with Affectometer (r = 0.63) and baseline negative mood
(r = 0.37). Prior negative mood, history of premenstrual
complaints, negative attitudes toward aging or meno-
pause, poor health, and daily hassles significantly pre-
dicted depressed mood.
The Norway HUNT-II study added further support to
evidence of increased depressive symptoms in the meno-
pause transition. Based on the Hospital Anxiety and
Depression Scale (HADS), a widely-published, brief self-
report measure that is validated to detect the presence
and severity of depression and anxiety in non-psychiatric
populations) [61], scores for depression and anxiety were
significantly higher for perimenopausal women com-
pared to premenopausal women [62].
Several studies evaluated the risk of clinical depression
in the menopause transition but had conflicting results.
In a study of 29 women who met clinical criteria for de-
pression, the risk of a depression onset was significantly
greater in the 2 years surrounding the final menstrual
period than in the preceding premenopausal years [63].
Two population-based studies extended these findings
[19, 36], although conclusions are limited by different
definitions of new onset depression in these studies.
A third community-based study utilized a standard
psychiatric interview to identify current major depression
over a 7-year time period; 42 cases of first-onset major de-
pression were identified, but no significant associations
were found between first-onset major depression andmenopausal status or reproductive hormone levels [57].
The identification of major depression is a strength of
the study. However, the small number of identified
cases may have yielded less reliable estimates, and in-
terpretation of the results must consider the possibility
of type 11 error.
The Harvard Study of Moods and Cycles enrolled a
second cohort to continue studies of new-onset depres-
sion in late reproductive-age women. Unexpectedly, the
rates of new-onset depression were extremely low in the
second cohort [64]. The risk of incident major depres-
sion or dysthymia over a 3-year period was 5.7 % in
cohort 1, but only 1.2 % in cohort 2, yielding a highly
significant difference (4.5 %, 95 % CI: 2.2, 6.8). An in-
depth analysis to determine possible sources of bias for
these disparate findings identified selection bias associ-
ated with self-referral of the participants and elements of
the study design as the likely reasons for the very
disparate rates of depression identified in the two co-
horts. These findings underscore the importance of
considering the possible impact of selection biases,
particularly in populations with differing racial and eco-
nomic conditions.
In summary, these longitudinal studies in the general
population consistently showed that depressive symp-
toms were greater in the menopause transition com-
pared to premenopause. However, the use of standard
diagnostic criteria for depressive illness was limited, and
evidence for an increased risk of diagnosed depressive
illness (rather than depressive symptoms) in the meno-
pause transition was less clear. This was emphasized in
another review of relationships between menopause and
depression, where the researchers concurred that “the
change in menopausal status over time was associated
with an increased risk of elevated depressive symptoms,
independent of demographic, psychosocial, behavioral
and health factors” [65]. However, when menopause-
associated depressions were distinguished from depres-
sive disorders, the more limited data from women with
depressive disorders were insufficient to conclude that
depressive illnesses occurred as a biological response to
hormonal changes in the menopause transition.
Hormone associations with depression in the menopause
transition
Associations of reproductive hormones with mood are
difficult to measure in large epidemiologic studies. Dif-
ferences in frequency and timing of measurements, assay
sensitivities and different statistical models in analysis of
the data contribute to the limited and inconsistent find-
ings of hormone associations with depression in the
menopause transition.
Accumulating data suggest that perimenopausal de-
pression is not simply due to low hormone levels, but
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characterize the transition to menopause, may be endo-
crine triggers for perimenopausal depression is some
women [14]. Evidence from clinical research and animal
models was reviewed by Gordon et al. as a basis for a
theoretical model for perimenopausal depression [21]. In
the conceptual model, ovarian hormone fluctuations,
particularly progesterone-derived neurosteroids, were
modulators of the GABA-ergic modulation of the
hypothalamic-pituitary-adrenal (HPA) axis. This may
sensitize vulnerable women to psychosocial stress and
potentially lead to increased vulnerability to depression
in some women. The researchers concluded that “this
proposed model provided a basis for understanding the
mechanisms by which the changing hormonal environ-
ment of the menopause transition may interact with the
psychosocial environment of midlife to contribute to risk
of perimenopausal depression”.
Another review considered the role of allopregnano-
lone, a stress-responsive regulator of neuronal function,
in triggering affective dysregulation in susceptible
women [66]. They concluded that the source of suscepti-
bility to affective disorder remains unclear, but evidence
in multiple animal models suggests that allopregnano-
lone may trigger mood symptoms, possibly as a function
of alterations in central neurotransmitter systems, pos-
sibly y-aminobutyric acid (GABA), consequent to allo-
pregnanolone withdrawal combined with stress.
Several epidemiologic studies have evaluated hormone
variability in relation to mood in the menopause transi-
tion with conflicting results. In an 8-year follow-up of
the SWAN cohort, testosterone levels and increased
testosterone from baseline were associated with an in-
creased likelihood of high depressive symptoms (CES-D
scores) (OR 1.15; 95 % CI: 1.01 – 1.31 and OR 1.23;
95 % CI: 1.04 – 1.45, respectively) [55]. There were no
associations with depressive symptoms of either levels or
changes in estradiol or FSH. A subsequent study of the
SWAN mental health sample evaluated these hormones
in relation to major depressive episode but found no sig-
nificant associations in the menopause transition [56].
In contrast, depressive symptoms adjusted for history
of depression, race, and age were significantly associated
with subject aggregate profiles of increased estradiol
levels in the menopause transition in the POAS cohort
(OR 1.27; 95 % CI: 1.00 – 1.60) [51]. In a subsequent
longitudinal study of women with no history of depres-
sion, significant hormone associations with the onset of
depressed mood included levels of follicle-stimulating
hormone (FSH), decreased levels of inhibin b, decreased
levels of luteinizing hormone (LH), and increased vari-
ability of estradiol, FSH and LH around the woman’s
own mean level of each hormone [19]. Among women
who met clinical diagnostic criteria for depressivedisorder, increased levels of FSH and LH, decreased
levels of inhibin b, and increased variability of estradiol
and FSH were significant associated with the first oc-
currence of depression in the menopause transition
(estradiol variability: OR 2.45; 95 % CI: 1.54 – 3.89).
Possibly differences in the frequency and timing of
hormone measures contributed to differing results
between these studies.
Findings differed in other community-based studies. In
the Melbourne study, a 2-year decline in estradiol levels
was the strongest risk factor for depressive symptoms,
adjusted for baseline depression, age and BMI (OR 3.41;
95 % CI: 1.24 – 9.36) [67]. While the findings suggested
a role for declining estradiol in depression, the partici-
pants were postmenopausal, aged 56–67 years, and the
assessments did not describe hormone associations with
depression in the menopause transition. In contrast, the
SMWHS found no significant association of urinary
measures of estrone, FSH, testosterone and cortisol with
depressed mood [33, 59]. A community-based, cross-
sectional study of women ages 45–54 years found that
25 % experienced depressed mood (CES-D > =16), but
there were no significant associations of depressed mood
with estradiol or androgens [68].
The association between depressive symptoms and an-
drogens of both adrenal and ovarian origin has also been
studied. Two cross-sectional studies showed an inverse
relationship between serum levels of dihydroepiandros-
terone sulfate (DHEAS) and depression [69, 70], while
longitudinal studies found either no significant associ-
ation [55] or a positive association between DHEAS
levels and depressive symptoms during the menopause
transition [71].
The association between testosterone levels and de-
pressive symptoms across the menopause transition is
also controversial. In the 10-year SMWHS, there was no
association between urinary testosterone levels and de-
pressive symptoms [59]. However, in the early SWAN
cohort, where the women were premenopausal or in the
early menopause transition, there was a significant
inverse association between testosterone and high de-
pressive symptoms [72]. The association reversed in an
8-year follow-up, where testosterone levels were posi-
tively associated with depressive symptoms [55]. Further
evidence from the Multiethnic Study of Atherosclerosis
(MeSA) showed a significant inverse relationship be-
tween free testosterone levels and high depressive symp-
toms among women who were in the first 10 years
postmenopause [73].
While these studies suggest possible associations of
hormone fluctuations or changes with depression in the
menopause transition, there are no definitive conclusions.
It can be emphasized again that differences in the fre-
quency and timing of hormone measurements, differences
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menopausal stages, and differing approaches and models
in data analysis contribute to conflicting results.
History of depression
A history of depression is one of the strongest predictors
of depressive symptoms and depressive disorders in the
menopause transition [18, 20, 51, 59, 74], with consistent
findings in a number of large cohort studies.
An early report in the Massachusetts Women’s Health
Study indicated that prior depression was the strongest
predictor of subsequent depression (CES-D), with an
odds ratio of 9.62 (95 % CI: 6.78– 13.70) [43]. In the
Harvard Study of Moods and Cycles, women with a his-
tory of depression had a 20 % increased rate of entering
the menopause transition sooner than women with no
history of depression [74]. In the SWAN mental health
study, the risk of MDD was three times greater for
women with a history of MDD compared to women
with no history of MDD (OR 2.98; 95 % CI: 1.55 – 5.72)
[56]. In a follow-up of this study, twice as many women
with a history of major depression (MDD) developed
MDD compared to women with no history of MDD (59
and 28 %, respectively) [20]. Women with a history of
depression in the POAS cohort had a 13 times greater
risk of depressive symptoms in the menopause transition
compared to women with no history of depression (OR
13.62; 95 % CI: 7.20 – 25.80, P < 0.001) [51]. In a longi-
tudinal study of the pattern of depressive symptoms
around menopause, approximately 50 to 65 % of women
with a history of depression had high CES-D scores in
the years before the FMP compared to 10 to 30 % of
women with no history of depression [18]. In another
large community-based, prospective study, women with
prior depression were two times more likely to report in-
creased depressive symptoms in the transition from pre-
to perimenopause (OR 1.98; 95 % CI: 1.47 – 2.67) [75].
Depression and vasomotor symptoms
Vasomotor symptoms (hot flashes and/or night sweats)
are the most frequently reported menopausal symptoms
across all races/ethnicities [76]. Many studies confirm
their prevalence, which peaks around menopause, when
more than 70 % of women report experiencing this
symptom [32, 77]. In spite of their common occurrence,
the etiology remains poorly understood, with diverse hy-
potheses and many associations with other behavioral,
psychological and physical factors. A leading hypothesis
is that hot flashes are triggered centrally by noradrener-
gic activation in association with changes in estrogen,
which is known to influence thermoregulatory func-
tioning [78]. While it is known that vasomotor symp-
toms are associated with changes in estradiol and
other reproductive hormones, including follicle-stimulatinghormone (FSH) and inhibin b, the associations are com-
plex and do not clearly explain their occurrence [79, 80].
Although vasomotor symptoms (VMS) are highly cor-
related with depressive symptoms, evidence for the
causal direction is conflicting. There are many differ-
ences in study designs, sample sizes and assessments of
both VMS and depression, as delineated in an extensive
review of the directional associations between VMS
and depressive symptoms or major depressive disorder
(MDD) [81]. The review included 17 cross-sectional
studies that examined associations between VMS and
depressive symptoms and 7 studies that examined the
association between VMS and major depressive dis-
order (MDD); another 10 studies assessed the risk of
women with VMS developing depressive symptoms,
and 2 studies examined the reverse direction, i.e., the
risk of women with high depressive symptoms devel-
oping VMS.
A statistically significant, positive association between
VMS and depressive symptoms was identified in 9 of 17
cross-sectional studies, with odds ratios ranging from
1.27 (95 % CI: 1.08 – 1.51) to 8.1 (95 % CI: 2.5 – 26.4)
[82, 83]. The researchers concluded that the evidence
consistently supported a positive association between
VMS and depressive symptoms, but the direction of
association remained unclear. Of the 7 studies that ex-
amined the association between VMS and major depres-
sion, only 2 studies reported a significant association
[63, 81], while 5 studies found no statistically significant
association. However, the researchers determined that
most of the 7 studies had moderate to high risk of bias
due to small samples, convenience sampling and missing
information, which strongly limited conclusions about
the association between VMS and major depression.
Ten studies evaluated the risk of women with VMS de-
veloping depressive symptoms, and 8 of these indicated
that VMS increased the risk of developing depressive
symptoms, with odds ratios ranging from 1.62 (95 % CI:
1.43 – 1.84) to 8.88 (95 % CI: 2.57 – 30.68) [55, 84].
These studies were determined to be methodologically
sound with adjustments for numerous covariates and
low risk of bias, consequently providing consistent evi-
dence for VMS increasing the risk of depressive symp-
toms. Further evidence was reported in a SWAN study,
which investigated a very narrow time interval to show
that VMS predicted next-day negative mood (OR 1.27;
95 % CI: 1.03 – 1.58); however, negative mood did not
predict next-day VMS [85].
Two studies evaluated the risk of women with high de-
pressive symptoms developing VMS, and both reported
a positive association to suggest that depressive symp-
toms were more likely to precede hot flashes in women
with no previous experience of either symptom [86, 79].
Women with consistently high depressive symptoms in
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VMS [86]. Of women who had no high depressive symp-
toms or hot flashes at baseline in the POAS, 24 % re-
ported depressive symptoms (high CES-D scores) before
reporting hot flashes in a 10-year follow-up [79]. In con-
trast, only 8 % of the women reported hot flashes before
reporting depressed mood.
Aims of this review did not include intervention stud-
ies, although they are clearly important for evaluating
changes in hormone levels and associations of these
changes with depressed mood and VMS. For example,
estradiol administered to women with a diagnosis of de-
pressive disorder in the menopause transition showed
that estradiol improved depression independent of the
presence of hot flashes [87]. In another study, estradiol
was administered to women who had depressive disor-
ders, hot flashes and disturbed sleep in the menopause
transition. Results indicated that increased estradiol
levels and improved sleep quality predicted improve-
ment in depressed mood, while reduction of hot flashes
did not improve depressed mood [88]. This evidence
suggested that in spite of high correlations between de-
pressive symptoms and VMS, these variables may have
distinct pathways, and hot flashes alone are not a likely
cause of depression around menopause.
These findings overall indicate that depressive symp-
toms and vasomotor symptoms frequently co-occur
around the menopause transition. Endocrine events are
a shared component of these symptoms but are not the
only factor in their development. Numerous studies sug-
gest that women with VMS have an increased risk of de-
veloping depressive symptoms, but the reverse direction
is also observed. Data further indicate that menopausal
depression can occur in the absence of VMS and that
the cause of depression is not likely due to VMS alone.
The studies suggest that VMS and depressive symptoms
may have different underlying pathways and/or are mod-
ulated by different exogenous or endogenous factors.
Further studies that are designed to unravel components
of these complex associations are needed.
Depression and poor sleep
Sleep difficulties are a common problem in the meno-
pause transition. About 30 % of adults have one or more
symptoms of insomnia, according to the American
Academy of Sleep Medicine [89], and these symptoms
are more prevalent in women, particularly in mid-life
[90–93]. While a high prevalence of poor sleep quality
in mid-life women is well-documented, several well-
designed studies concluded that influences of both
age and menopausal status on poor sleep were modest
[92, 93]. In addition, while there is considerable evi-
dence that sleep difficulties are correlated with de-
pressive symptoms, poor sleep is a core symptom ofclinical depression [94, 95], which frequently makes it
difficult to determine whether sleep difficulties are a
component of or independent of depressed mood or clin-
ical depression.
The causal direction of poor sleep and depressed
mood is particularly difficult to disentangle, in part due
to the chronic nature of sleep problems, the episodic na-
ture of depression and the many definitions of both dis-
orders. The long-held domino hypothesis, i.e., that the
association between sleep problems and depressed mood
was driven by vasomotor symptoms has only partial sup-
port. For example, sleep problems predicted next-day
negative mood, but an association with vasomotor symp-
toms was found only in women who had depression at
the study baseline [96]. In an intervention study of
women who had depressive disorders, increasing levels
of estradiol and improved sleep quality predicted im-
provement in depressed mood in perimenopausal
women, but improved hot flashes did not improve de-
pressed mood [88]. The researchers concluded that
changes in estradiol and sleep quality, rather than hot
flashes, may mediate depression during the menopause
transition.
A recent study of the association of poor sleep, mood
and reproductive status found a significant association
between depressive symptoms and sleep impairment in
peri- and postmenopausal women but no consistent as-
sociation in younger premenopausal women [97].
Reports from the SWAN cohort indicated that 31 % of
the participants reported at least one of three evaluated
sleep difficulties and identified significant associations
between sleep difficulties and progression through the
menopause transition [98].
In contrast, other studies found no significant associ-
ation between depressed mood and poor sleep in peri-
menopausal women in adjusted analysis [99, 100]. In the
study of Cheng et al. [100], anxiety was related to all
assessed sleep problems but may have obscured an asso-
ciation with depressed mood due to high correlation of
these variables. In an evaluation of poor sleep in relation
to the final menstrual period, premenopausal sleep sta-
tus was the strongest predictor of poor sleep in the
menopause transition, and there was no further increase
in poor sleep around the final menstrual period [101].
Again, methodological differences may contribute to
conflicting findings, as for example, in the latter study,
where most participants were not clinically depressed
and poor sleep was reported at a premenopausal base-
line. Measures of depression and anxiety were highly
correlated, and anxiety rather than depression had the
stronger association with poor sleep in these studies.
In summary, the findings show a high prevalence of
sleep difficulties in mid-life women, but associations
between increased risk of poor sleep in relation to
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time. Depressive symptoms and sleep difficulties are
common, the symptoms are correlated and both may in-
crease around menopause. The causal directions and as-
sociations between these variables and the hormonal
changes of ovarian aging as well as other psychosocial
factors remain unclear.
Other factors associated with menopausal depression
Numerous studies have identified significant associations
of health, psychosocial and demographic variables with
depressed mood around menopause, but evidence for
the extent to which these factors are confounding or
independently associated with depressed mood or clin-
ical depression in perimenopausal women is inconsistent
or lacking. Associations with depressive symptoms
around menopause have been reported for health prob-
lems [54, 102], anxiety [57, 103], poor sleep and vaso-
motor symptoms [49, 79, 104–106], behavioral factors
such as smoking and obesity [51, 54, 107], stress and
negative life events [49, 53, 54, 57, 63, 107, 108], physical
activity [109, 110], marital and relationship issues
[59, 102], financial problems [54, 59], and demo-
graphic variables including race/ethnicity and education
[19, 51, 54, 58]. Overall, the data support the possibility
that depressed mood in the menopause transition is
multifactorial and not simply due to menopausal status
alone. It is possible that psychosocial and lifestyle factors,
together with health experience, have more effect on de-
pressed mood than endocrine changes. Although endo-
crine changes may be a trigger, the causal pathways
remain unclear [31, 102].
Another important question that remains open is
whether a first-onset depression in the menopause tran-
sition is etiologically or qualitatively different from re-
current depression. Several studies evaluated risk factors
for a first-onset depression in the menopause transition
for women with no history of depression. The risk of a
first depression was significantly greater for women who
reported vasomotor symptoms and for women who had
a history of adverse life events in the Harvard Study of
Moods and Cycles [36]. Vasomotor symptoms, high BMI
and smoking were independent contributors to first on-
set of depressive symptoms in the POAS study [19].
Vasomotor symptoms at a trend level, prior health con-
ditions and negative perceptions of functioning were risk
factors for first onset of major depression in midlife
women in the SWAN mental health study [20].
Steinberg et al. compared women with first-onset
versus recurrent clinical depression and found that
depressive symptom scores and measures of FSH did not
differ between the two groups [111]. In the SWAN men-
tal health study, the only risk factor uniquely associated
with onset of major depression among women with nohistory of major depression was vasomotor symptoms
(OR 2.09; 95 % CI: 1.26 – 3.47) [20].
Again, methodological differences may contribute to
disparate findings. Different risk factors were evaluated
and comparisons of menopausal status were not consist-
ent across the studies. Furthermore, the risk factors
identified for first-onset depression were also identified
in studies that included women with recurrent depression,
thus limiting conclusions. At present, there is no definitive
evidence of distinct risks of a first-onset depression versus
recurrent depression around menopause.
Limitations and future directions
The majority of studies of depressed mood in the meno-
pause transition reviewed here evaluated depressive
symptoms, which are important for screening depression
in the population and in clinical settings. Depressive
symptoms are highly correlated with clinical diagnosis of
depression but are not equivalent. Some studies evalu-
ated samples with a diagnosis of depression, but reports
of association between clinical depression and meno-
pausal status are conflicting, and further studies are
needed to determine whether the risk of diagnosed
depression is increased around menopause. Studies of
depression cross many domains, and this review did not
include intervention or neuroendocrine studies, or in-
depth consideration of the many of the identified psy-
chosocial, behavioral and physical health factors that are
important for understanding depression in midlife
women. Other reviews are needed to address these areas.
The reviewed studies were from different cohorts and
population samples, and conclusions should be consid-
ered cautiously, particularly in comparing studies that
differ in racial and social economic distributions, as
recently demonstrated by Harlow et al. [64].
The greatest challenges for further research are to
identify endocrine and genetic elements that may under-
lie depression and disentangle psychosocial factors that
are associated with this disorder. Epidemiologic and
clinical questions for further study include identifying
the pattern and associated risk factors of depression fol-
lowing the final menstrual period; increasing informa-
tion about associations between reproductive hormone
changes and mood; further clarifying effects of hormone
treatments on mood in perimenopausal women; deter-
mining confounding factors and causal directions of
vasomotor symptoms and sleep difficulties in relation to
depression and the extent to which these variables are
associated with hormonal changes of menopause; disen-
tangling depression and its associations with other major
health problems of mid-life women such as cardiovascu-
lar disease, metabolic syndrome and osteoporosis. Longi-
tudinal studies that clearly define menopausal stages,
hormone measurements that are adequate for the
Freeman Women's Midlife Health  (2015) 1:2 Page 9 of 11questions and repeated measures of standard mood and
behavioral assessments are important for increased un-
derstanding of women’s health in relation to menopause.Conclusions
While the changing hormonal milieu is experienced by
all women around menopause, only a minority experi-
ence debilitating depressive symptoms in this transition
period. Accumulating evidence indicates that depressive
symptoms, and possibly clinical depression, increase in
the menopause transition compared to premenopause.
There is also evidence that the changing endocrine mi-
lieu is associated with increased depressive symptoms,
but hormones are clearly not the only factor. Further
studies are needed to understand the development of
depression in women around menopause.
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